26
Participants
Start Date
September 19, 2017
Primary Completion Date
January 2, 2020
Study Completion Date
May 31, 2026
Sofosbuvir-velpatasvir (400 mg/100 mg)
Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
Ex Vivo Lung Perfusion (EVLP)
Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
University Health Network Toronto General Hospital, Toronto
Collaborators (1)
Gilead Sciences
INDUSTRY
University Health Network, Toronto
OTHER